Age, mean ± SD yr | 56.6 ± 10.6 | 57.4 ± 10.9 | 53.1 ± 8.6 | 57.0 ± 10.6 | 52.0 ± 9.3 |
|
29–49 | 46 | | | | |
|
50–69 | 98 | | | | |
|
70+ | 17 | | | | |
|
Menopause | 111 (68.9) | 71.5 | 58.1 | 68.7 | 72.7 |
|
Neoadjuvant therapy | 19 (11.8) | 13.1 | 6.5 | 12.0 | 9.1 |
|
Postoperative chemotherapy | 60 (37.3) | 33.8 | 51.6 | 35.3 | 63.6 |
|
Tamoxifen | 94 (58.4) | 56.2 | 67.7 | 56.7 | 81.8 |
|
Aromatase inhibitor | 105 (65.2) | 62.3 | 77.4 | 65.3 | 63.6 |
|
Tumour status | | | | | |
|
T0 | 19 (11.8) | 12.3 | 9.7 | 12.0 | 9.1 |
|
T1 | 100 (62.1) | 62.3 | 67.7 | 62.7 | 72.7 |
|
T2 | 33 (20.5) | 20.0 | 16.1 | 20.0 | 9.1 |
|
T3 | 5 (3.1) | 3.1 | 3.2 | 2.7 | 9.1 |
|
T4 | 4 (2.5) | 2.3 | 3.2 | 2.7 | 0.0 |
|
Node status |
|
N0 | 104 (64.6) | 66.2 | 51.7 | 63.1 | 70.0 |
|
N1 | 43 (26.7) | 26.9 | 31.0 | 28.9 | 10.0 |
|
N2 | 13 (8.1) | 6.2 | 17.2 | 7.4 | 20.0 |
|
N3 | 1 (0.6) | 0.8 | 0.0 | 0.7 | 0.0 |
|
HER2-neu positive, n = 140 | 23 (16.4) | 12.4 | 33.3 | 12.4 | 63.6 |
|
Partial mastectomy | 130 (80.7) | 81.5 | 77.4 | 80.7 | 81.8 |
|
Total mastectomy | 31 (19.3) | 18.5 | 22.6 | 19.3 | 18.2 |
|
Axillary dissection | 91 (56.5) | 56.9 | 54.8 | 56.7 | 54.5 |
|
Hormone replacement therapy | 59 (36.6) | 41.5 | 16.1 | 38.0 | 18.2 |
|
Patient’s history of cancer | 9 (5.6) | 6.9 | 0.0 | 6.0 | 9.1 |
|
Family history of cancer | 16 (9.9) | 10.8 | 6.5 | 10.7 | 9.1 |
|
Family history of breast cancer | 52 (32.3) | 35.2 | 23.3 | 32.7 | 27.3 |
|
Other chronic medication | 29 (18.0) | 21.5 | 3.2 | 19.3 | 9.1 |